A recent survey of US rheumatologists found that there is room for improvement in clinicians' awareness of biosimilar therapies.
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.